Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02864485 |
Title活体肝移植治疗无法切除的结直肠癌肝转移灶 | 阶段
不适用
|
Date Added 2016-08-12 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03494946 |
Title结直肠癌患者肝移植与化疗的比较 | 阶段
不适用
|
Date Added 2018-04-11 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03796884 |
TitleLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-01-08 |
地点
Pennsylvania, United States
Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Linaclotide |
标签
MSS/ MMRp
|
| NCT ID NCT06099821 |
TitleKN046联合瑞戈非尼或阿帕替尼治疗对PD-1/PD-L1阻断剂耐药的MSI-H消化系统癌症 | 阶段
第二阶段
|
Date Added 2023-10-25 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
apatinib, KN046, Regorafenib |
标签
MSI-H/ MMRd
|
| NCT ID NCT03667170 |
TitleKN035 for dMMR/MSI-H Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2018-09-12 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT06634875 |
TitleIsunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) | 阶段
第二阶段
|
Date Added 2024-10-10 |
地点
California, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT03867799 |
TitleiSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | 阶段
第二阶段
|
Date Added 2019-03-08 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT06047015 |
TitleIrreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-09-21 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID LUMINESCENCE |
TitleIpilimumab, Maraviroc and Nivolumab (LUMINESCENCE) | 阶段
第 1 阶段
|
Date Added 2019-01-25 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT02668770 |
TitleIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | 阶段
第 1 阶段
|
Date Added 2016-01-29 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Ipilimumab, MGN1703 |
标签
MSS/ MMRp
|
